Sustained Release Formulation Gains Traction as Patient-Centric Therapies Drive Innovation

The pharmaceutical industry is increasingly embracing Sustained Release Formulation technologies as a means to improve patient adherence, reduce dosing frequency, and optimize therapeutic outcomes. From chronic disease management to targeted local therapies, sustained release systems are becoming a cornerstone of modern drug development.

2026-06-02

Peptide Drug Substance Manufacturing Powers Next-Generation Therapeutics

The global pharmaceutical landscape is being reshaped by the rising prominence of peptide drug substances, driven by the success of peptide-based therapies in treating chronic diseases such as diabetes, obesity, and cancer.

2026-05-26

Injectable Formulation Development Gains Momentum as Biologics and Complex Molecules Drive Demand

The pharmaceutical industry is witnessing a surge in demand for Injectable Formulation Development, fueled by the rapid expansion of biologics, peptide therapies, and complex small molecules. As more drug candidates require parenteral administration for optimal efficacy, the need for robust, scalable, and compliant injectable formulations has never been greater.

2026-05-19

JiuzhouPharma at API China 2026

2026-05-14

Small Molecule APIs Drive Next-Generation Pharmaceutical Innovation and Supply Chain Resilience

The global pharmaceutical industry is undergoing a profound shift, yet small molecule APIs remain the backbone of modern therapeutics. Despite the rise of biologics and advanced modalities,

2026-05-12

Topical Formulation Services Accelerate Innovation in Dermatology and Drug Delivery

The pharmaceutical sector is experiencing rapid growth in Topical Formulation Services, driven by increasing demand for targeted, non-invasive therapies. As dermatology pipelines expand and new delivery technologies emerge, Topical Formulation Services are becoming essential for translating complex molecules into safe, effective treatments for patients worldwide.

2026-04-30

Connecting Global Innovation Resources to Accelerate CDMO Capabilities | JiuzhouPharma Launches “Isolated Lab” in Japan

2026-04-24

2025 Jiuzhou Pharma ESG report

2026-04-23

GMP Small Molecule Manufacturing Enters a New Era of Innovation and Expansion

The global pharmaceutical industry is witnessing rapid transformation as GMP small molecule manufacturing continues to evolve alongside new therapeutic demands. With small molecules still accounting for a significant share of approved drugs, the importance of GMP small molecule production remains central to ensuring safety, quality, and scalability in modern drug development.

2026-04-23

Peptide API Manufacturing Enters a New Era of Innovation and Global Expansion

The global pharmaceutical industry is witnessing a significant transformation driven by advances in Peptide API Manufacturing. As peptide-based therapeutics gain traction in treating chronic diseases such as diabetes, obesity, and cancer, demand for high-quality peptide active pharmaceutical ingredients continues to surge. This trend is reshaping the landscape of Peptide API Manufacturing, pushing contract development and manufacturing organizations (CDMOs) to innovate and scale rapidly to handle this increasing demand.

2026-04-16

JiuZhou Pharma Selected for S&P Global’s Sustainability Yearbook (China Edition) 2026

2026-04-14

Topical Formulation CDMO Gains Momentum as Demand for Advanced Drug Delivery Surges

The global pharmaceutical outsourcing landscape is witnessing rapid transformation, with Topical Formulation CDMO services emerging as a key growth engine. As demand for dermatological and localized therapies continues to rise, Topical Formulation CDMO providers are playing an increasingly strategic role in accelerating drug development and commercialization.

2026-04-09